Related Experiment Video
Updated: Jun 5, 2026
06:14
Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue
Published on: May 8, 2018
Neuroprotective therapeutics for Alzheimer's disease: progress and prospects
1MS Therapeutics Ltd, Beechey House, 87 Church Street, Crowthorne, Berkshire RG45 7AW, UK. alan.palmer@mstherapeutics.com
Trends in Pharmacological Sciences
|January 25, 2011
Summary
Alzheimer's disease (AD) is increasing, necessitating new treatments. Understanding AD's neurobiology offers hope for medications to slow or halt disease progression.
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- Alzheimer's disease (AD) prevalence is rising globally, particularly in aging populations.
- The increasing burden of AD necessitates urgent development of safe and effective pharmacotherapies.
- Advances in understanding AD etiology and pathophysiology fuel hope for disease-modifying treatments.
Purpose of the Study:
- To review the neurobiological underpinnings of Alzheimer's disease.
- To discuss current advancements in developing neuroprotective therapeutics for AD.
- To explore future prospects for Alzheimer's disease pharmacotherapy.
Main Methods:
- Literature review of neurobiological basis of AD.
- Analysis of current progress in neuroprotective therapeutics.
- Exploration of future therapeutic strategies for AD.
Main Results:
- The review covers the neurobiological basis of AD, including neuronal loss, plaques, and tangles.
- Current progress in developing neuroprotective agents is discussed.
- Future prospects for pharmacotherapy in managing AD are examined.
Conclusions:
- A deeper understanding of AD's neurobiology is crucial for therapeutic development.
- Neuroprotective strategies hold promise for slowing or halting AD progression.
- Continued research is essential to combat the growing Alzheimer's disease burden.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...